MS (EI): Found, 238.1567 m/z (Mϩ, C14H22O3 requires 238.1569);
Acknowledgements
Compound 7: Rf = 0.27 (hexane–EtOAc, 9 : 1); 1H NMR (500 MHz,
CDCl3): δ 1.31 (6H, m, 4-, 5-, 6-H), 1.45 (2H, m, 7-H), 1.59 (2H, m,
3-H), 2.20–2.30 (4H, m, 2-, 8-H), 3.66 (3H, s, -OCH3), 6.07 (1H, dd,
J 7.9 and 15.3, 12-H), 6.16–6.34 (2H, m, 9-, 10-H), 7.08 (1H, dd,
J 10.1 and 15.3, 11-H), 9.52 (1H, d, J 7.9, 13-H); HR-MS (EI):
Found, 238.1567 m/z (Mϩ, C14H22O3 requires 238.1569).
We are grateful for using the Mass and NMR spectrometers
of the MS laboratory (Faculty of Agriculture), the API and
SC-NMR laboratories of Okayama University.
8 (a) H. Boechzelt, B. Karten, P. M. Abuja, W. Sattler and M. Mittel-
bach, J. Lipid Res., 1998, 39, 1503–1507; (b) A. D. Watson, N.
Leitinger, M. Navab, K. F. Faull, S. Horrko, J. L. Witzum, W. Palin-
ski, D. Schwenke, R. G. Salomon, W. Sha, G. Subbanagounder, A.
M. Fogelman and J. A. Berliner, J. Biol. Chem., 1997, 272, 13597–
13607 and the references therein.
References
‡ Protection of the aldehyde group is not expected to eliminate double
bond isomerization because the deprotection step involves acidic
conditions.
§ The composition of such core aldehydes in vivo is not known, but
besides possible isomerization of the (Z,E)-isomer as presented above,
both isomers are expected to form directly from the corresponding
nonenzymatically-produced (Z,E) and (E,E)-hydroperoxides.
9 N. Baba, K. Yoneda, S. Tahara, J. Iwasa, T. Kaneko and M. Matsuo,
J. Chem. Soc., Chem. Commun., 1990, 18, 1281–1282.
1
10 Compound 1: H NMR (500 MHz, CDCl3): δ 0.87 (t, 3H, ω-CH3),
1.18–1.35 (34H, m, CH2 × 17), 1.45 (2H, m, 7Ј-H), 1.60 (4H, m,
OCOCH2 CH2 × 2), 2.20–2.30 (6H, m, 8Ј-H, OCOCH2 × 2), 3.35
(9H, s, NMe3), 3.79 (2H, m, OCH2CH2N), 3.94 (2H, m, CH2OP),
4.11 (1 proton of OCH2CH(OR)CH2OP), 4.31(2H, m, OCH2-
CH2N), 4.38 (1H, d, 1 proton of OCH2CH(OR)CH2OP), 5.19 (1H,
br s, OCH2CH(OR)CH2OP), 6.00 (1H, m, 9Ј-H), 6.14 (1H, dd, J 7.9
and 15.2, 12Ј-H), 6.26 (1H, t, J 11.4, 10Ј-H), 7.44 (1H, dd, J 11.4 and
15.2, 11Ј-H), 9.61 (1H, d, J 7.9, 13Ј-H); ES MS: Found, 730.6 m/z;
HR-FAB MS: Found, 730.5032 m/z (C39H72NO9P ϩ Hϩ requires
730.5023); Compound 2: same as for 1 except: 6.07 (1H, dd, J 7.9,
15.3, 12Ј-H), 6.16–6.34 (2H, m, 9Ј, 10Ј-H), 7.08 (1H, dd, J 10.1 and
15.3, 11Ј-H), 9.52 (1H, d, J 7.9, 13Ј-H).
1 For a recent review, see: A. Kuksis, inform (AOCS), 2000, 11,
746–752.
2 A. Tokumura, T. Sumida, M. Toujima, K. Kogure, K. Fukuzawa,
Y. Takahashi and S. Yamamoto, J. Lipid Res., 2000, 41, 953–962.
3 For recent reviews, see: (a) C. D. Funk and T. Cyrus, Trends in
Cardiovascular Medicine, 2001, 11, 116–124; (b) M. K. Cathcart and
V. A. Folcik, Free Rad. Biol. Medicine, 2000, 28, 1726–1734.
4 G. Hoppe, A. Ravandi, D. Herrera, A. Kuksis and H. F. Hoff,
J. Lipid Res., 1997, 38, 1347–1360.
5 A. N. Onyango, T. Inoue, S. Nakajima, N. Baba, T. Kaneko,
M. Matsuo and S. Shimizu, Angew. Chem., Int. Ed. Engl., 2001, 40,
1755–1757.
11 Compound 3: Rf = 0.44 (hexane–EtOAc, 9 : 1); 1H NMR (500 MHz,
CDCl3): δ 0.5–2.6 (57H, CH3 × 5, CH2 × 18, CH × 6), 4.59 (1H, m,
3-H), 5.38 (1H, m, 6-H), 6.00 (1H, m, 9Ј-H), 6.14 (1H, dd, J 7.9 and
15.2, 12Ј-H), 6.26 (1H, t, J 11.4, 10Ј-H), 7.44 (1H, dd, J 11.4 and
15.2, 11Ј-H), 9.61 (1H, d, J 7.9, 13Ј-H); HR-FAB MS: Found,
593.4932 (C40H64O3 ϩ Hϩ requires 593.4933); Compound 4: Rf = 0.35
6 T. Nishike, S. Kondo, T. Yamamoto, A. Shigeeda, Y. Yamamoto,
H. Takamura and T. Matoba, Biosci. Biotechnol. Biochem., 1997, 61,
1973–1976.
7 Compound 6: Rf = 0.31 (hexane–EtOAc, 9 : 1); 1H NMR (500 MHz,
CDCl3): δ 1.31 (6H, m, 4-, 5-, 6-H), 1.45 (2H, m, 7-H), 1.59 (2H, m,
3-H), 2.20–2.30 (4H, m, 2-, 8-H), 3.66 (3H, s, -OCH3), 6.00 (1H, m,
9-H), 6.14 (1H, dd, J 7.9 and 15.2, 12-H), 6.25 (1H, t, J 11.4, 10-H),
7.44 (1H, dd, J 11.4 and 15.2, 11-H), 9.61 (1H, d, J 7.9, 13-H); HR-
1
(hexane–EtOAc, 9 : 1); H NMR same as for 3 except: δ 6.07 (1H,
dd, J 7.9 and 15.3, 12Ј-H), 6.16–6.34 (2H, m, 9Ј-, 10Ј-H), 7.08 (1H,
dd, J 10.1 and 15.3, 11Ј-H), 9.52 (1H, d, J 7.9, 13Ј-H).
J. Chem. Soc., Perkin Trans. 1, 2002, 1941–1943
1943